Management of Atopy with Dupilumab and Omalizumab in CADINS Disease-Reference-Cited by-同舟云学术

Management of Atopy with Dupilumab and Omalizumab in CADINS Disease

Published:2024-01-17 Issue:2 Volume:44 Page:
ISSN:0271-9142
Container-title:Journal of Clinical Immunology
language:en
Short-container-title:J Clin Immunol

Author:

Diaz-Cabrera Natalie M.,Bauman Bradly M.,Iro Mildred A.,Dabbah-Krancher Gina,Molho-Pessach Vered,Zlotogorski Abraham,Shamriz Oded,Dinur-Schejter Yael,Sharon Tatyana Dubnikov,Stepensky Polina,Tal Yuval,Eisenstein Eli M.,Pietzsch Leonora,Schuetz Catharina,Abreu Damien,Coughlin Carrie C.,Cooper Megan A.,Milner Joshua D.,Williams Anthony,Armoni-Weiss Gil,Snow Andrew L.,Leiding Jennifer W.^ORCID

Funder

Jeffrey Modell Foundation

St. Louis Children's Hospital

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10875-023-01636-y.pdf

Reference38 articles.

1. Kim HO. Targeting cytokines and signaling molecules related to immune pathways in atopic dermatitis: therapeutic implications and challenges. Arch Pharm Res. 2022;45(12):894–908.

2. Salvati L, Liotta F, Annunziato F, Cosmi L. Therapeutical targets in allergic inflammation. Biomedicines. 2022;10(11):2874. https://doi.org/10.3390/biomedicines10112874.

3. Dixit C, Thatayatikom A, Pappa H, Knutsen AP. Treatment of severe atopic dermatitis and eosinophilic esophagitis with dupilumab in a 14-year-old boy with autosomal dominant hyper-IgE syndrome. J Allergy Clin Immunol Pract. 2021;9(11):4167–9.

4. Matucci-Cerinic C, Viglizzo G, Pastorino C, Corcione A, Prigione I, Bocca P, et al. Remission of eczema and recovery of Th1 polarization following treatment with dupilumab in STAT3 hyper IgE syndrome. Pediatr Allergy Immunol. 2022;33(4):e13770.

5. Nihal A, Comstock JR, Holland KE, Singh AM, Seroogy CM, Arkin LM. Clearance of atypical cutaneous manifestations of hyper-IgE syndrome with dupilumab. Pediatr Dermatol. 2022;39(6):940–2.